High blood pressure can lead to liver fibrosis – the gradual stiffening of your liver as thin bands of scar tissue gradually ...

Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...

Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

Hepatocellular carcinoma continues to pose a diagnostic challenge, particularly in the setting of underlying pathomorphological changes in the liver due to cirrhosis, steatosis, or steatohepatitis.

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

One place this happens is around the belly button, where tiny veins in the abdominal wall expand and become visible under the ...

Liver doctors and researchers share what it really means to detox from alcohol, and the profound benefits of this decision on ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, researchers have identified a vulnerability that opens ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...

Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.